Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Tsutomu Yoshikawa is active.

Publication


Featured researches published by Tsutomu Yoshikawa.


American Journal of Pathology | 2008

G-Protein-Coupled Receptor GPR49 is Up-regulated in Basal Cell Carcinoma and Promotes Cell Proliferation and Tumor Formation

Keiji Tanese; Mariko Fukuma; Taketo Yamada; Taisuke Mori; Tsutomu Yoshikawa; Wakako Watanabe; Akira Ishiko; Masayuki Amagai; Takeji Nishikawa; Michiie Sakamoto

The significance of Hedgehog (HH) signaling in the development of basal cell carcinoma (BCC) has been established. Although several target genes of HH signaling have been described previously, their precise role in tumorigenesis and cell proliferation is not yet known. To identify genes responsible for tumor formation in BCC, we screened a DNA microarray database of human BCC cases; the orphan G-protein-coupled receptor GPR49 was found to be up-regulated in all cases. GPR49 is a novel gene reported to be a marker of follicular and other tissue stem cells. Using real-time quantitative RT-PCR analysis, significant expression of GPR49 mRNA was observed in 19 of 20 BCC cases (95%) compared with controls. Up-regulation of GPR49 was confirmed by in situ hybridization. Moreover, knockdown of mouse Gpr49 showed suppression of cell proliferation in a mouse BCC cell line, and overexpression of GPR49 in human immortalized keratinocyte HaCaT cells induced proliferation. Furthermore, HaCaT cells overexpressing GPR49 showed tumor formation when transplanted into immunodeficient mice. In addition, inhibition of the HH signaling pathway in a mouse BCC cell line down-regulated endogenous Gpr49, whereas activation of HH signaling in mouse NIH3T3 cells up-regulated endogenous GPR49. These results suggest that GPR49 is expressed downstream of HH signaling and promotes cell proliferation and tumor formation in cases of BCC.


American Journal of Pathology | 2011

Membrane-Bound Serine Protease Inhibitor HAI-1 Is Required for Maintenance of Intestinal Epithelial Integrity

Makiko Kawaguchi; Naoki Takeda; Shinri Hoshiko; Kenji Yorita; Takashi Baba; Akira Sawaguchi; Yuriko Nezu; Tsutomu Yoshikawa; Tsuyoshi Fukushima; Hiroaki Kataoka

Hepatocyte growth factor activator inhibitor type 1 (HAI-1), encoded by the serine protease inhibitor Kunitz type 1 (SPINT1) gene, is a membrane-bound serine protease inhibitor expressed in epithelial tissues. Mutant mouse models revealed that HAI-1/SPINT1 is essential for placental labyrinth formation and is critically involved in regulating epidermal keratinization through interaction with its cognate cell surface protease, matriptase. HAI-1/SPINT1 is abundantly expressed in both human and mouse intestinal epithelium; therefore, we analyzed its role in intestinal function using mice with intestinal epithelial cell-specific deletion of Spint1 generated by interbreeding mice carrying Spint1(LoxP) homozygous alleles with transgenic mice carrying the Cre recombinase gene controlled by the intestine-specific Villin promoter. Although the resulting mice had normal development and appearance, crypts in the proximal aspect of the colon, including the cecum, exhibited histologic abnormalities and increased apoptosis and epithelial cell turnover accompanied by increased intestinal permeability. Distended endoplasmic reticula were observed ultrastructurally in some crypt epithelial cells, indicative of endoplasmic reticular stress. To study the role of HAI-1/SPINT1 in mucosal injury, we induced colitis by adding dextran sodium sulfate to the drinking water. After dextran sodium sulfate treatment, intestine-specific HAI-1/SPINT1-deficient mice had more severe symptoms and a significantly lower survival rate relative to control mice. These results suggest that HAI-1/SPINT1 plays an important role in maintaining colonic epithelium integrity.


Immunology | 2001

Rat mast cell protease-I enhances immunoglobulin E production by mouse B cells stimulated with interleukin-4

Tsutomu Yoshikawa; Teruaki Imada; Hiroshi Nakakubo; Norifumi Nakamura; Koji Naito

Mast cell chymase plays important roles in inflammation and tissue remodeling. Here we show that mast cell chymase also functions as an enhancer of immunoglobulin production. In the culture of murine spleen cells stimulated with lipopolysaccharide and interleukin‐4, purified rat chymase (rat mast cell protease‐I; RMCP‐I), at physiological concentrations, enhanced immunoglobulin E (IgE) and IgG1 syntheses but not IgG3 synthesis. The enhancement was also evident when spleen cells depleted of T cells and macrophages were employed as responding cells. Enzymatic activity of RMCP‐I was required to enhance IgE and IgG1, because two inhibitors for chymotryptic enzymes, chymostatin and Y‐40613, a novel chymase inhibitor, suppressed the enhanced immunoglobulin production, and phenylmethylsulphonyl fluoride, an irreversible inhibitor for serine proteases, totally abolished the enhancing effect. Furthermore, a specific inhibitor for Zn2+‐dependent metalloproteases, GI 129471, could also completely inhibit the production of IgE and IgG1 that was enhanced by RMCP‐I, suggesting that a metalloprotease also played an essential role in the immunoglobulin production. Our results together with others show that proteases from mast cell granules have important function not only in the efferent phase but also in the afferent phase of immune responses.


Life Sciences | 2006

Y-40138, a multiple cytokine production modulator, protects against d-galactosamine and lipopolysaccharide-induced hepatitis

Tetsuko Fukuda; Akira Mogami; Hideki Tanaka; Tsutomu Yoshikawa; Masao Hisadome; Hirotsugu Komatsu


Japanese Journal of Pharmacology | 2002

Therapeutic potential of a specific chymase inhibitor in atopic dermatitis.

Teruaki Imada; Naruyasu Komorita; Fujio Kobayashi; Koji Naito; Tsutomu Yoshikawa; Mizuo Miyazaki; Norifumi Nakamura; Takao Kondo


Archive | 1999

IgE ANTIBODY PRODUCTION INHIBITORS AND AUTOIMMUNE DISEASES INHIBITORS

Fujio Kobayashi; Shigeki Kuwahara; Naruyasu Komorita; Koji Naito; Teruaki Imada; Tsutomu Yoshikawa


The Journal of Allergy and Clinical Immunology | 2000

792 Therapeutic potential of specific chymase inhibitor in atopic dermatitis

Teruaki Imada; Naruyasu Komorita; Fujio Kobayashi; Shigeki Kuwahara; Koji Naito; Tsutomu Yoshikawa; Mizuo Miyazaki; Takao Kondo; Norifumi Nakamura


Archive | 2005

Preventive and/or Therapeutic Agent for Cancer

Tsutomu Yoshikawa; Wakako Watanabe; Yoko Hirakawa


Archive | 2005

Preventive and/or remedy for cancer

Tsutomu Yoshikawa; Wakako Watanabe; Yoko Hirakawa


Archive | 2004

Use of heterocyclic amide in production of autoimmune diseases inhibitors

Naruyasu Komorita; Tsutomu Yoshikawa; Teruaki Imada; Fujio Kobayashi; Koji Naito; Shigeki Kuwahara

Collaboration


Dive into the Tsutomu Yoshikawa's collaboration.

Top Co-Authors

Avatar

Teruaki Imada

Tokyo Institute of Technology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Koji Naito

Green Cross International

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge